{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T18:51:12Z","timestamp":1788375072678,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,29]]},"DOI":"10.7759\/cureus.65617","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T07:54:10Z","timestamp":1722239650000},"source":"Crossref","is-referenced-by-count":2,"title":["Tigecycline-Based Regimens for Complicated Urinary Tract Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria: Case Series"],"prefix":"10.7759","author":[{"given":"Cristian-Mihail","family":"Niculae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Evelina","family":"Gorea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura-Georgiana","family":"Tirlescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca-Mihaela","family":"Matoru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Hristea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-020-04121-1","article-title":"Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review","volume":"41","author":"Yaghoubi S","year":"2022","unstructured":"Yaghoubi S, Zekiy AO, Krutova M, et al.. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. Eur J Clin Microbiol Infect Dis. 2022, 41:1003-22. 10.1007\/s10096-020-04121-1","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12020234","article-title":"Carbapenem-resistant Klebsiella pneumoniae: virulence factors, molecular epidemiology and latest updates in treatment options","volume":"12","author":"Karampatakis T","year":"2023","unstructured":"Karampatakis T, Tsergouli K, Behzadi P. Carbapenem-resistant Klebsiella pneumoniae: virulence factors, molecular epidemiology and latest updates in treatment options. Antibiotics (Basel). 2023, 12:10.3390\/antibiotics12020234","journal-title":"Antibiotics (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhazmat.2023.131889","article-title":"The tigecycline resistance gene tetX has an expensive fitness cost based on increased outer membrane permeability and metabolic burden in Escherichia coli","volume":"458","author":"Chen T","year":"2023","unstructured":"Chen T, Zhao MX, Tang XY, et al.. The tigecycline resistance gene tetX has an expensive fitness cost based on increased outer membrane permeability and metabolic burden in Escherichia coli. J Hazard Mater. 2023, 458:131889. 10.1016\/j.jhazmat.2023.131889","journal-title":"J Hazard Mater"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul M","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, et al.. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022, 28:521-47. 10.1016\/j.cmi.2021.11.025","journal-title":"Clin Microbiol Infect"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.53854\/liim-3004-5","article-title":"Role of tigecycline in the treatment of urinary tract infections: a systematic review of published case reports","volume":"30","author":"Charles R","year":"2022","unstructured":"Charles R, Adhikari SD, Mittal A, et al.. Role of tigecycline in the treatment of urinary tract infections: a systematic review of published case reports. Infez Med. 2022, 30:516-24. 10.53854\/liim-3004-5","journal-title":"Infez Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/8755122513519332","article-title":"Role of tigecycline for the treatment of urinary tract infections","volume":"30","author":"Wu G","year":"2014","unstructured":"Wu G, Abraham T, Saad N. Role of tigecycline for the treatment of urinary tract infections. J Pharm Technol. 2014, 30:87-92. 10.1177\/8755122513519332","journal-title":"J Pharm Technol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq116","article-title":"Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation","volume":"65","author":"Nix DE","year":"2010","unstructured":"Nix DE, Matthias KR. Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation. J Antimicrob Chemother. 2010, 65:1311-2. 10.1093\/jac\/dkq116","journal-title":"J Antimicrob Chemother"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1086\/648720","article-title":"Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials","volume":"50","author":"Gardiner D","year":"2010","unstructured":"Gardiner D, Dukart G, Cooper A, Babinchak T. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin Infect Dis. 2010, 50:229-38. 10.1086\/648720","journal-title":"Clin Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku189","article-title":"Tigecycline in treatment of multidrug-resistant Gram-negative bacillus urinary tract infections: a systematic review","volume":"69","author":"Brust K","year":"2014","unstructured":"Brust K, Evans A, Plemmons R. Tigecycline in treatment of multidrug-resistant Gram-negative bacillus urinary tract infections: a systematic review. J Antimicrob Chemother. 2014, 69:2606-10. 10.1093\/jac\/dku189","journal-title":"J Antimicrob Chemother"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.21037\/tau-20-959","article-title":"Efficacy and safety of tigecycline for complicated urinary tract infection: a systematic review","volume":"10","author":"Liu YX","year":"2021","unstructured":"Liu YX, Le KJ, Shi HY, et al.. Efficacy and safety of tigecycline for complicated urinary tract infection: a systematic review. Transl Androl Urol. 2021, 10:292-9. 10.21037\/tau-20-959","journal-title":"Transl Androl Urol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4212\/cjhp.v65i3.1144","article-title":"Tigecycline treatment of urinary tract infection and prostatitis: case report and literature review","volume":"65","author":"Bates D","year":"2012","unstructured":"Bates D, Parkins M, Hellweg R, Gibson K, Bugar JM. Tigecycline treatment of urinary tract infection and prostatitis: case report and literature review. Can J Hosp Pharm. 2012, 65:209-15. 10.4212\/cjhp.v65i3.1144","journal-title":"Can J Hosp Pharm"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2014.10.024","article-title":"ESCMID guideline for the diagnosis and treatment of biofilm infections 2014","volume":"21 Suppl 1","author":"H\u00f8iby N","year":"2015","unstructured":"H\u00f8iby N, Bjarnsholt T, Moser C, et al.. ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. Clin Microbiol Infect. 2015, 21 Suppl 1:S1-25. 10.1016\/j.cmi.2014.10.024","journal-title":"Clin Microbiol Infect"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1086\/650482","article-title":"Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America","volume":"50","author":"Hooton TM","year":"2010","unstructured":"Hooton TM, Bradley SF, Cardenas DD, et al.. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010, 50:625-63. 10.1086\/650482","journal-title":"Clin Infect Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1754133","article-title":"Colistin and its role in the Era of antibiotic resistance: an extended review (2000-2019)","volume":"9","author":"El-Sayed Ahmed MA","year":"2020","unstructured":"El-Sayed Ahmed MA, Zhong LL, Shen C, Yang Y, Doi Y, Tian GB. Colistin and its role in the Era of antibiotic resistance: an extended review (2000-2019). Emerg Microbes Infect. 2020, 9:868-85. 10.1080\/22221751.2020.1754133","journal-title":"Emerg Microbes Infect"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02449-14","article-title":"In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant Enterobacteriaceae","volume":"58","author":"Betts JW","year":"2014","unstructured":"Betts JW, Phee LM, Hornsey M, Woodford N, Wareham DW. In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2014, 58:3541-6. 10.1128\/AAC.02449-14","journal-title":"Antimicrob Agents Chemother"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2018.1516270","article-title":"In-vitro activities of imipenem-colistin, imipenem-tigecycline, and tigecycline-colistin combinations against carbapenem-resistant Enterobacteriaceae","volume":"30","author":"Dundar D","year":"2018","unstructured":"Dundar D, Duymaz Z, Genc S, Er DK, \u0130rvem A, Kandemir N. In-vitro activities of imipenem-colistin, imipenem-tigecycline, and tigecycline-colistin combinations against carbapenem-resistant Enterobacteriaceae. J Chemother. 2018, 30:342-7. 10.1080\/1120009X.2018.1516270","journal-title":"J Chemother"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2016.12.008","article-title":"Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum \u03b2-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance","volume":"50","author":"Ku YH","year":"2017","unstructured":"Ku YH, Chen CC, Lee MF, Chuang YC, Tang HJ, Yu WL. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum \u03b2-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance. J Microbiol Immunol Infect. 2017, 50:931-9. 10.1016\/j.jmii.2016.12.008","journal-title":"J Microbiol Immunol Infect"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.08.011","article-title":"Tigecycline: a glycylcycline antimicrobial agent","volume":"28","author":"Doan TL","year":"2006","unstructured":"Doan TL, Fung HB, Mehta D, Riska PF. Tigecycline: a glycylcycline antimicrobial agent. Clin Ther. 2006, 28:1079-106. 10.1016\/j.clinthera.2006.08.011","journal-title":"Clin Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw255","article-title":"True incidence of tigecycline-induced pancreatitis: how many cases are we missing?","volume":"71","author":"Davido B","year":"2016","unstructured":"Davido B, Shourick J, Makhloufi S, Dinh A, Salomon J. True incidence of tigecycline-induced pancreatitis: how many cases are we missing?. J Antimicrob Chemother. 2016, 71:2994-5. 10.1093\/jac\/dkw255","journal-title":"J Antimicrob Chemother"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022638","article-title":"Hypofibrinogenemia induced by high-dose tigecycline-case report and review of literature","volume":"99","author":"Fan Q","year":"2020","unstructured":"Fan Q, Huang W, Weng Y, Xie X, Shi Z. Hypofibrinogenemia induced by high-dose tigecycline-case report and review of literature. Medicine (Baltimore). 2020, 99:e22638. 10.1097\/MD.0000000000022638","journal-title":"Medicine (Baltimore)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/278312-tigecycline-based-regimens-for-complicated-urinary-tract-infections-caused-by-carbapenem-resistant-gram-negative-bacteria-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T07:54:14Z","timestamp":1722239654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/278312-tigecycline-based-regimens-for-complicated-urinary-tract-infections-caused-by-carbapenem-resistant-gram-negative-bacteria-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.65617","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,29]]}}}